İslam El Yazmalarının Bilgi Kaynağı Olarak Kullanılması ve Dijital Ortamda Bilgiye Erişiminin Geliştirilmesi

---

SÜMBÜL S. (Yürütücü)

TÜBİTAK Projesi, 2019 - 2020

• Proje Türü: TÜBİTAK Projesi
• Başlama Tarihi: Ekim 2019
• Bitiş Tarihi: Nisan 2020

Proje Özeti

Regulatory B cells in myasthenia gravis are differentially affected by therapies

Vuslat Yilmaz¹, Solene Maillard², Frederique Truffault², Francis Bolgert³, Anthony Behin⁴,

Jean-Francois Regnard⁵, Sonia Berrih-Aknin² & Rozen Le Panse²

1Department of Neuroscience, Aziz Sancar Institute of Experimental Medical Research (DETAE), Istanbul University, Istanbul, Turkey

2Center of Research in Myology, Sorbonne University, INSERM, AIM, UMRS974, Paris, France

3Department of Neurology, APHP, Pitie-Salp^etriere Hospital, Paris, France

4Neuromuscular Disease Center, APHP, AIM, Pitie-Salpetriere Hospital, Paris, France

5Department of Thoracic Surgery, Cochin Hospital of Paris, APHP, Rene Descartes University, Paris, France

 

We analyzed the number and functionality of regulatory B (Breg) cells in welldefined myasthenia gravis patients. We first showed a decreased number of circulating CD19+CD24++CD38++ Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells.

Ann Clin Transl Neurol. 2018 Sep 22;5(11):1408-1414. doi: 10.1002/acn3.645.